ReviewTrends in pharmacological sciences2013
Computational methods for drug design and discovery: focus on China.
Review in Trends in pharmacological sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Synthesis and in vitro/in silico evaluation studies of arensulfonylhydrazinoxamoyl amine and amino acid derivatives as preliminary acetylcholinesterase inhibitors.Scientific reports · 2026Article
- Computer-Aided Drug Design in Research on Chinese Materia Medica: Methods, Applications, Advantages, and Challenges.Pharmaceutics · 2025Review
- 3D-QSAR, design, molecular docking and dynamics simulation studies of novel 6-hydroxybenzothiazole-2-carboxamides as potentially potent and selective monoamine oxidase B inhibitors.Frontiers in pharmacology · 2025Article
- Conformation Study and Design of Novel 6-Hydroxybenzothiazole-2- Carboxamides as Potentially Potent and Selective Monoamine Oxidase B Inhibitors for Neuroprotection.Current topics in medicinal chemistry · 2025Article
- In Silico Study of the Potential of Brazilein Sappan Wood as a Beta-Lactamase Inhibitor against Extended-Spectrum Beta-Lactamase-Encoding Genes.The Malaysian journal of medical sciences : MJMS · 2024Article
- HBCVTr: an end-to-end transformer with a deep neural network hybrid model for anti-HBV and HCV activity predictor from SMILES.Scientific reports · 2024Article
- Docking strategies for predicting protein-ligand interactions and their application to structure-based drug design.Communications in information and systems · 2024Article
- Phytochemical profile, physicochemical, antioxidant and antimicrobial properties ofFrontiers in chemistry · 2024Article
- Sequence-based drug design as a concept in computational drug design.Nature communications · 2023Article
- Insight into TLR4 receptor inhibitory activityRSC advances · 2023Article
- A Transformer-Based Ensemble Framework for the Prediction of Protein-Protein Interaction Sites.Research (Washington, D.C.) · 2023Article
- Plant Metabolites as SARS-CoV-2 Inhibitors Candidates: In Silico and In Vitro Studies.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway.Journal of cellular and molecular medicine · 2021Article
- In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis.Applied biochemistry and biotechnology · 2021Review
- Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases.Briefings in bioinformatics · 2019Review
- Target-based drug discovery through inversion of quantitative structure-drug-property relationships and molecular simulation: CA IX-sulphonamide complexes.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.Frontiers in chemistry · 2018Review
- Network-Based Methods for Prediction of Drug-Target Interactions.Frontiers in pharmacology · 2018Review
- Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening.Frontiers in pharmacology · 2018Article
- Computer-Aided Drug Design in Epigenetics.Frontiers in chemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decades, China's computational drug design and discovery research has experienced fast development through various novel methodologies. Application of these methods spans a wide range, from drug target identification to hit discovery and lead optimization. In this review, we firstly provide an overview of China's status in this field and briefly analyze the possible reasons for this rapid advancement. The methodology development is then outlined. For each selected method, a short background precedes an assessment of the method with respect to the needs of drug discovery, and, in particular, work from China is highlighted. Furthermore, several successful applications of these methods are illustrated. Finally, we conclude with a discussion of current major challenges and future directions of the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.